Ana Isabel Fernandes

Prof. Ana Isabel Fernandes

Instituto Universitário Egas Moniz, Caparica, Portugal
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GPGabriela G. Pereira
Gabriela G. Pereira
SFSara Figueiredo
Sara Figueiredo
Ana Isabel FernandesAna Isabel Fernandes
Ana Isabel Fernandes
JPJoao Pinto
Joao Pinto
Three-dimensional (3D) printing offers the greatest potential to revolutionize the future of pharmaceutical manufacturing by overcoming challenges of conventional pharmaceutical operations and focusing design and production of dosage forms on the patient’s needs. Of the many technologies available, fusion deposition modelling (FDM) is considered of the lowest cost and higher reproducibility and accessibility, offering clear advantages in drug delivery. FDM requires in-house production of filaments of drug-containing thermoplastic polymers by hot-melt extrusion (HME), and the prospect of connecting the two technologies has been under investigation. The ability to integrate HME and FDM and predict and tailor the filaments’ properties will extend the range of printable polymers/formulations. Hence, this work revises the properties of the most common pharmaceutical-grade polymers used and their effect on extrudability, printability, and printing outcome, providing suitable processing windows for different raw materials. As a result, formulation selection will be more straightforward (considering the characteristics of drug and desired dosage form or release profile) and the processes setup will be more expedite (avoiding or mitigating typical processing issues), thus guaranteeing the success of both HME and FDM. Relevant techniques used to characterize filaments and 3D-printed dosage forms as an essential component for the evaluation of the quality output are also presented.

1 April 2001 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Ana Isabel FernandesAna Isabel Fernandes
Ana Isabel Fernandes
GGGregory Gregoriadis
Gregory Gregoriadis

1 August 1997 in Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology
Verified
Journal Article
Closed access
Ana Isabel FernandesAna Isabel Fernandes
Ana Isabel Fernandes
GGGregory Gregoriadis
Gregory Gregoriadis

1 January 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
EME. Massarelli
E. Massarelli
DSD. Silva
D. Silva
APA.F.R. Pimenta
A.F.R. Pimenta
Ana Isabel FernandesAna Isabel Fernandes
Ana Isabel Fernandes
JMJ.L.G. Mata
J.L.G. Mata
Ana Paula SerroAna Paula Serro
Ana Paula Serro

1 December 2000 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
GGG. Gregoriadis
G. Gregoriadis
Ana Isabel FernandesAna Isabel Fernandes
Ana Isabel Fernandes
MMM. Mital
M. Mital
BMB. McCormack
B. McCormack

25 June 2012 in Journal of Microencapsulation
Verified
Journal Article
Closed access
MCM. Teresa Calejo
M. Teresa Calejo
AAAntonio Almeida
Antonio Almeida
Ana Isabel FernandesAna Isabel Fernandes
Ana Isabel Fernandes
A microparticulate protein delivery system was developed using collagen, from the medusa Catostylus tagi, as a polymeric matrix. Collagen microparticles (CMPs) were produced by an emulsification-gelation-solvent extraction method and a high loading efficiency was found for the entrapment of lysozyme and α-lactalbumin. CMPs were cross-linked with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The uncross-linked CMPs were spherical, rough-surfaced, presenting an estimated median size of 28 µm by laser diffraction. Upon cross-linking, particle size (9.5 µm) and size distribution were reduced. CMPs showed a moderate hydrophobic behaviour and a positive surface charge. Cross-linking also resulted in greater stability in water, allowing a slow release, as shown by in vitro experiments. The assessment of lysozyme's biological activity showed that the protein remained active throughout the encapsulation and cross-linking processes. In summary, the work herein described shows the potential use of a marine collagen in the production of microparticles for the controlled release of therapeutic proteins.